Central Research Associates Inc

1. GlaxoSmithKline, LLC. $3,249,715 366 payments
2. AbbVie, Inc. $606,396 85 payments
3. Pfizer Inc. $582,524 75 payments
4. Allergan Inc. $401,257 47 payments
5. Janssen Research & Development, LLC $337,859 23 payments
6. Moderna TX, Inc. $320,215 27 payments
7. AstraZeneca UK Limited $286,930 7 payments
8. AstraZeneca Pharmaceuticals LP $77,258 3 payments
9. Sanofi US Services Inc. $60,911 18 payments
10. Endo Pharmaceuticals Inc. $47,600 11 payments

1. Study name not reported $1,253,658 143 payments
2. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $1,040,144 107 payments
3. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $835,186 97 payments
4. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $435,279 49 payments
5. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $313,505 25 payments
6. A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyroid compared to levothyroxine (T4) in previously hypothyroid participants, who are on euthyroid T4 replacement $273,232 14 payments
7. A Randomized Open Label Study Drug Dose Blind Multi Center Study to Evaluate the Efficacy and Safety of JNJ70033093 BMS986177 an Oral Factor XIa Inhibitor Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery $164,892 2 payments
8. Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) $164,236 2 payments
9. A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $163,357 9 payments
10. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $150,546 9 payments

1. Other $10,400 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.